Stifel raised the firm’s price target on Tandem Diabetes (TNDM) to $16 from $15 and keeps a Hold rating on the shares. Going into the Q3 print, the implied Q4 step-up appeared to hit Tandem’s FY25 revenue guidance, though better-than-expected Q3 results allow the Q4 bar to come down as Tandem’s overall 2025 revenue guide remained unchanged, the analyst tells investors in a research note. The firm added that its concerns remain around pump share until the company’s pipeline takes hold, and the limited amount of visibility into price realization in the pharmacy channel.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $16 from $14 at Goldman Sachs
- Tandem Diabetes price target raised to $18 from $16 at Mizuho
- Tandem Diabetes Care: Strong Buy Rating Backed by Strategic Growth Initiatives and Attractive Valuation
- Tandem Diabetes price target raised to $55 from $51 at Barclays
- Tandem Diabetes price target raised to $18 from $16 at Baird